Use of Semen TEX101 to Improve Sperm Retrieval Rates for Men With Non-obstructive Azoospermia
1 other identifier
interventional
200
2 countries
3
Brief Summary
The investigators hypothesize that sperm production varies with time in men with no sperm in semen (non-obstructive azoospermia, NOA) and that the semen protein, TEX101, is able to monitor these changes. The investigators further hypothesize that TEX101 levels may be used to predict the optimum time for microsurgical testicular sperm extraction (mTESE) to provide the highest successful rates of sperm retrieval.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Feb 2016
Longer than P75 for not_applicable
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2016
CompletedFirst Submitted
Initial submission to the registry
July 11, 2016
CompletedFirst Posted
Study publicly available on registry
August 2, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2020
CompletedMarch 12, 2019
March 1, 2019
3.8 years
July 11, 2016
March 8, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Successful testicular sperm retrieval
This outcome will be measured by if sperms would be found during the procedure or if sperms would be identified in the IVF clinic.
2 years
Secondary Outcomes (2)
Natural variation in sperm counts in semen
2 years
Natural variation in semen TEX101 concentration
2 years
Study Arms (1)
TEX101
OTHERThis is a single arm study. All patients will be asked to provide multiple semen samples and all samples will be tested with TEX101 ELISA assay. Timing of mTESE maybe changed according to the assay results.
Interventions
Eligibility Criteria
You may qualify if:
- Diagnosed with NOA by standard clinical means with a minimum of 2 semen tests confirming that the man is azoospermic
- Ability to understand the study and consent
- Ability to deliver semen samples
You may not qualify if:
- Men do not have NOA
- Cannot understand the study and consent
- Cannot provide semen samples
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Mount Sinai Hospital, Canadalead
- Canadian Institutes of Health Research (CIHR)collaborator
- Weill Medical College of Cornell Universitycollaborator
- McGill Universitycollaborator
- University of California, San Franciscocollaborator
- The Physicians' Services Incorporated Foundationcollaborator
Study Sites (3)
University of California, San Francisco
San Francisco, California, 94143, United States
Weill Cornell Medical College
New York, New York, 10065, United States
St. Mary's Hospital
Montreal, Quebec, QC H3T 1M5, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Keith Jarvi, MD
Mount Sinai Hospital, Canada
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 11, 2016
First Posted
August 2, 2016
Study Start
February 1, 2016
Primary Completion
December 1, 2019
Study Completion
December 1, 2020
Last Updated
March 12, 2019
Record last verified: 2019-03